After the FDA approval, TRITON2 and TRITON3 mCRPC studies were initiated in order to determine how patients with prostate cancer will respond to the<unk>  drug. The studies for these two trials are still going on and the estimated dates for the first results are range between 2019 and 2022. The ARIEL3 and ARIEL4 are two randomized, double-blind phase III studies. The ARIEL3 study was designed to evaluate the effect of the investigational agent as a maintenance treatment for the advanced platinum-sensitive ovarian cancer patients compared placebo after their response to at least two prior chemotherapies. The top-line results from the study were presented at the ESMO 2017 congress and right after that, it was published in the Lancet journal in September 2017. The findings showed significant improvement in progression-free survival (PFS) in patients treated with Rubraca than placebo. Recently, in October 2017, a supplemental sNDA for the<unk>  ARIEL3 maintenance treatment has been submitted to the FDA. The ARIEL4 trial is still ongoing to evaluate how patients will best respond to treatment with<unk>  compared with chemotherapy. The estimated data collection date for primary outcome measurement will be in June 2022.
Rucaparib
Olaparib
Decitabine
Zalcitabine
Martinostat
Apricitabine
Trifluridine
Panobinostat